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Background: Friedreich’s ataxia (FRDA) is the most common hereditary autosomal recessive form of ataxia. In this
disease there is early manifestation of gait ataxia, and dysmetria of the arms and legs which causes impairment in
daily activities that require fine manual dexterity. To date there is no cure for this disease. Some novel therapeutic
approaches are ongoing in different steps of clinical trial. Development of sensitive outcome measures is crucial to
prove therapeutic effectiveness. The aim of the study was to assess the reliability and sensitivity of quantitative and
objective assessment of upper limb performance computed by means of the robotic device and to evaluate the
correlation with clinical and functional markers of the disease severity.
Methods: Here we assess upper limb performances by means of the InMotion Arm Robot, a robot designed for
clinical neurological applications, in a cohort of 14 children and young adults affected by FRDA, matched for age
and gender with 18 healthy subjects. We focused on the analysis of kinematics, accuracy, smoothness, and
submovements of the upper limb while reaching movements were performed. The robotic evaluation of upper
limb performance consisted of planar reaching movements performed with the robotic system. The motors of the
robot were turned off, so that the device worked as a measurement tool. The status of the disease was scored
using the Scale for the Assessment and Rating of Ataxia (SARA). Relationships between robotic indices and a range
of clinical and disease characteristics were examined.
Results: All our robotic indices were significantly different between the two cohorts except for two, and were
highly and reliably discriminative between healthy and subjects with FRDA. In particular, subjects with FRDA
exhibited slower movements as well as loss of accuracy and smoothness, which are typical of the disease. Duration
of Movement, Normalized Jerk, and Number of Submovements were the best discriminative indices, as they were
directly and easily measurable and correlated with the status of the disease, as measured by SARA.
Conclusions: Our results suggest that outcome measures obtained by means of robotic devices can improve the
sensitivity of clinical evaluations of patients’ dexterity and can accurately and efficiently quantify changes over time
in clinical trials, particularly when functional scales appear to be no longer sensitive.
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Friedreich’s ataxia (FRDA) is the most common heredi-
tary autosomal recessive form of ataxia resulting from
the homozygous expansion of a guanine–adenine–adenine
(GAA) trinucleotide repeat in intron 1 of the frataxin gene
on chromosome 9q13. FRDA affects about 1 in 30,000 in-
dividuals in Western Europe [1]. The clinical features of
FRDA are progressive ataxia, weakness, spasticity, sensory
symptoms and cardiomyopathy [2,3].
In patients with FRDA, gait ataxia and general clumsi-
ness are the commonest presenting symptoms and upper
limb ataxia progresses slower than lower limb impairment,
thus the majority of non-ambulatory patients can still use
their upper limbs for daily activities. Consequently, spe-
cific tools for assessing upper limb function may then be
suitable both for ambulatory and non-ambulatory patients
and valuable for long-term evaluation [4].
Currently, the effectiveness of treatment is generally
measured by clinical scales that include several func-
tional tests like the Friedreich Ataxia Rating Scale
(FARS) [5], the International Cooperative Ataxia Rating
Scale (ICARS) [6], the brief version of ICARS named
Brief Ataxia Rating Scale (BARS) [7], and the Scale for
the Assessment and Rating of Ataxia (SARA) [8]. SARA
was recognized as the most sensitive scale for its high con-
struct validity, best effect size and for its compact nature
in a longitudinal analysis of a numerous cohort of 96
FRDA patients in comparison with ICARS and FARS
[9,10], although the scores of these scales are well corre-
lated with each other. The applicability of these functional
scales in children is still an open question, as age-
validation is needed. However, SARA was demonstrated
to be suitable with a good reliability in healthy children
beyond the age of 10. Moreover, in a preliminary pilot
study concerning age-dependency, it emerges that SARA
is more suitable for long-term quantitative ataxia assess-
ment from child to adulthood in comparison to ICARS
and BARS [11].
In general, however, clinical evaluations exhibit several
limitations: a low rate of reproducibility, low resolution,
lack of sensitivity, and floor and ceiling effects [12].
Therefore, in the last few years, researchers have devel-
oped a growing interest in the quantitative evaluation
techniques of residual motor abilities, especially those
focusing on the upper limb function. Such efforts have
been primarily motivated by the inherent ability of ro-
botic devices to objectively quantify motor performance
and to detect small variations; consequently, robot medi-
ated evaluations could represent a useful additional tool
for clinical measures [13,14]. Briefly, robot devices are
effectively employed to assess motor recovery of the
upper limbs mainly in patients with stroke [15-22] (for
reviews, see [23] and [24]) and in children with cerebral
palsy [25-28] and the mounting evidence suggests thatrobotic outcomes can also be effectively employed in
other diseases, such as Multiple Sclerosis [29].
Up to now, only a few studies have aimed to a quanti-
tative evaluation of the motor performance of upper
limbs in patients with ataxia [30-34] and even fewer
studies focused on individuals with FRDA. Day et al.
[35] reported that analyzing the influence of vision on
upper limb reaching movements by using an optical
tracker system, FRDA patients showed prolonged reac-
tion times and less accurate and slower movements
compared to healthy subjects. Bardorfer et al. [36], by
using an haptic interface, showed that FRDA patients
were able to perform tracking tasks, but with lower vel-
ocity and less accuracy than a healthy control group; the
relationship between the robotic indices and clinical
scales was not investigated and the movement was not
partitioned into submovements, which were recognized
as significant for the analysis of neurological disease pro-
gression [37,38]. Finally, Maurel et al. [39] developed
and applied an upper limb kinematic protocol adapted
to children and young adults with FRDA; they highlighted
lower values of velocity, precision and smoothness of
movements of upper limbs in three tasks - i.e. pointing,
circle-drawing and prono-supination tasks - in comparison
with a control group.
Therefore, the aim of this study was to assess with a
robotic system the upper limb performances in a cohort
of children and young adults affected by FRDA and age
and gender-matched with healthy subjects. We analyzed
the kinematics, accuracy, smoothness, and submove-
ments of the upper limb during a planar point-to-point
reaching task in a dual-modal visual-haptic feedback by
means of the InMotion Arm Robot, the commercial ver-
sion of the MIT-Manus [40].
Specifically, the purposes of this paper are threefold.
Firstly, to study the discriminative sensitivity of the
selected indices computed via the robotic system between
healthy subjects and patients with FRDA. Secondly, to
assess the reliability of the selected indices. Finally, to
evaluate the correlation between the indices provided by
the robotic system and a range of clinical and disease
characteristics in subjects with FRDA. We hypothesized
that the indices of upper limb performance would be asso-
ciated with disease severity, as evaluated by SARA, and
with disease-related variables, as disease duration and
number of GAA repeats, which are variables well known
in literature highly related with the phenotype [41].
Methods
Subjects
Fourteen genetically confirmed individuals affected by
FRDA (mean age 15.3 years, range 6–28 years, 4 males,
10 females) were recruited at the Neurorehabilitation
Division of the IRCCS Bambino Gesù Children’s Hospital
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assistance, two patients needed walking aids, and one was
non ambulatory. Eye movements were evaluated in all pa-
tients as a part of the neurological evaluation. Almost
all patients had mild oculomotor abnormalities with fix-
ation instability, square wave jerks, and, rarely, nystag-
mus. None of them wore lens for visual refractive deficit
or presented limitation of Range of Motion at the level
of the elbow and the shoulder. Clinical features and
genetic information for FRDA patients, together with
demographic data, are reported in Table 1. The status
of the disease was scored using SARA. Eighteen age
and gender-matched [42,43] healthy subjects (mean age
15.1 years, range 7–28 years, 5 males, 13 females) were
also enrolled as a control group. Inclusion criteria for
healthy subjects were absence of neurological and visual
deficits, and a physiological Range of Motion for elbow
and shoulder.
All the subjects, except for one FRDA patient, were
right handed. Hand dominance was established as the
hand that participants used for writing and personal ac-
tivities. All subjects were naïve to the robotic device and
the task.
The Ethics Committee of the Children’s Hospital ap-
proved the experimental protocol, which was explained,
together with the aims of the research, to the subjects
involved in the study and children’s parents. Written con-
sent was obtained from all adults and children’s parents.
Equipment
The assessment of upper limb motor performance was
conducted by means of the InMotion Arm Robot (Inter-
active Motion Technologies Inc., Watertown, MA - USA,Table 1 Demographic data and clinical information for patien
FRDA
subjects
Sex Hand
dominance
Age (years, months) SARA (total score
1 F R 9, 3 9.5
2 F R 12, 7 21.5
3 F R 14, 4 15.5
4 F R 6, 1 3.5
5 M R 13, 1 14
6 F R 28, 1 6
7 F L 14, 9 9
8 M R 14, 1 10
9 M R 28, 0 2.5
10 F R 8, 6 9
11 F R 14, 9 8
12 F R 17, 1 24.5
13 M R 14, 3 9.5
14 F R 26, 7 39
na: not available.see Figure 1A), a robot designed for clinical neurological
applications [44]. It is based on a direct-drive, five-bar-
linkage SCARA (Selective Compliance Assembly Robot
Arm) mechanism that provides two translational degrees
of freedom, restricting the hand motion to the horizontal
plane. When motors are turned off, the highly backdriva-
ble, low-friction robot does not interfere with motion and
allows the individual to freely move the end-effector. It is
also equipped with sensors that provide the position of
the end-effector (with an accuracy of 100 μm) with a sam-
pling rate of 200 Hz. A screen located in front of the sub-
ject shows the position of the end-effector, together with
the exercise to be performed.
Clinical assessment
The status of the disease was rated by the same neurolo-
gist specializing in ataxia by using the Scale for the Assess-
ment and Rating of Ataxia (SARA) [8], a clinical scale
with total scores ranging from 0 (no ataxia) to 40 (most
severe ataxia). It includes eight items: (i) gait (0–6 points);
(ii) stance (0–6 points); (iii) sitting (0–4 points); (iv)
speech disturbance (0–6 points); (v) finger chase (0–4
points); (vi) nose-finger test (0–4 points); (vii) fast alternat-
ing hand movement (0–4 points); and, finally, (viii) heel-
shin slide (0–4 points). Upper limb impairment score of
SARA is the sum of the previously indicated items v, vi
and vii.
Robotic evaluation
The robotic evaluation of upper limb performance
consisted of planar reaching movements performed
with the robotic system. Subjects were comfortably
seated on a chair, with their hand grasping the end-ts with Friedreich’s ataxia.
) SARA (upper limb score) GAA
smaller
GAA
longer
Disease duration
(years)
3 780 1115 3
4 633 633 6
7.5 930 1066 7
1.5 682 848 1
3 600 750 6
1 na na 8
2 715 900 7
3 780 780 6
0.5 na na 9
3 1014 1347 3
2 264 1347 5
6,5 900 1000 8
2,5 805 1064 5
16 790 790 12
Figure 1 (A) Robotic system for upper limb rehabilitation; (B) Visual template of the reaching task. The yellow circle indicates the position of the
end-effector while the target to be reached is showed by the red circle.
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ments, the trunk was restrained by a five-point seat-
belt. An orthotic device supported the forearm and
the hand to prevent all wrist movements and forearm
prono-supination. The center of the workspace was lo-
cated in front of the subject at the midline of the body.
The position (height and distance from the table) of
the chair was set depending on the subject’s anthropo-
metric measures, so that, handling the end-effector
with the orthotic device in the center of the work-
space, the elevation angle of the shoulder was 45 de-
grees for all the participants.
The protocol consisted of five blocks of 16 unassisted
planar reaching movements, making a total of 80
reaching movements. In a single block, eight white tar-
gets equally spaced on a circumference (with radius of
14 cm), and a white target positioned in the center of
the circumference were shown on the screen located in
front of the subject, together with the end-effector pos-
ition (Figure 1B). The center of the circumference was
coincident with the center of the workspace. Starting
from the center, subjects were asked to move the end-
effector, with a self-selected speed, in order to reach
the blinking target and to come back to the center fol-
lowing the visual feedback in a virtual environment,
along a straight path of about 14 cm; additionally the
participants were not asked to perform the task with a
specific time constraint and, then, the movement ac-
curacy was implicitly a task requisite. The trial involves
only the shoulder and elbow planar coordination. The
sequence of center-out movements was randomized.
The motors of the robot were turned off, so that the
device worked as a measurement tool. Only the domin-
ant arm was tested. The session per subject/patient
lasted less than 20 minutes. Both patients and healthy
subjects were tested twice, to assess the test-retest reli-
ability of the proposed outcome measures. The time
interval between testing was 1–7 days.Data analysis
Data measured by the robot were processed offline to
obtain quantitative indices related to different features
of the subject’s dexterity. The recorded end-effector
position was filtered with a 6th order zero phase shift
low-pass Butterworth filter, with a cut-off frequency of
10 Hz, and differentiated to obtain speed, acceleration,
and jerk. Then, from the global measure, we identified
the 80 reaching movements: specifically, each move-
ment was considered to start when the speed magni-
tude became greater than 10% of the peak speed and
the movement was considered to end when the speed
dropped and remained below the 10% of the peak speed
[20]. For each movement, a set of indices was com-
puted. Among feasible measures proposed in the litera-
ture on neuro-rehabilitation of the upper limb [20,45]
to characterize movement smoothness, movement ac-
curacy, and tracking rapidity, we selected the following
indices grouped as: kinematic, accuracy, smoothness,
and submovement indices.
Kinematic indices
To characterize the kinematics of the movement, we
measured: (i) the Duration of Movement (D), defined as
the time between the movement onset and the move-
ment termination, (ii) the Mean Velocity (MV) and (iii)
the Peak Velocity (PV) values of the velocity profile [19].
Accuracy indices
The Length Ratio (LR) is defined as the ratio between
the path actually travelled by the subject and the desired
one (Lt), i.e. the minimum distance between the begin-
ning and the end of the trajectory [20]:
LR ¼
X
dR
Lt
ð1Þ
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trajectory. Higher values of LR represent a lower accur-
acy value.
The Lateral Deviation (LD) is defined as the highest
deviation from the straight line that connects the initial
and the final target position in the analyzed movement
[27]. The LD value increases when accuracy decreases.
The Aiming Angle (AA) is computed as the angle be-
tween the line connecting the starting and ending target,
and the line from the starting point to the peak speed
point [19]. An AA decrease corresponds to an increase
of accuracy.
Smoothness indices
The Normalized Jerk (NJ) is expressed by the following
equation [46]:
NJ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
2
Z
j2⋅
T 5X
dR
 2 ⋅dt
vuuut ð2Þ
where j is the jerk, i.e. the derivative of acceleration, and
T is the duration of the movement. Lower values of NJ
indicate smoother movements.
The Speed Metric (SM) is measured as the ratio be-
tween the mean and the peak speed [13]:
SM ¼ vmean
vpeak
ð3Þ
The SM value increases when smoothness increases.
Submovement indices
With respect to the submovements, we followed the ap-
proach proposed by Friedman et al. [47]. Specifically, we
decomposed the reaching movements into submove-
ments, modeled according to minimum jerk criterion
with a bell-shape velocity profile [48]:
_x tð Þ ¼ A
D
30
t−t0
D
 4
−60
t−t0
D
 3
þ 30 t−t0
D
 2 
ð4Þ
where D, A and t0 are the duration, the amplitude and
the starting time of a single submovement, respectively.
Each velocity profile F(t) of the reconstructed movement
is then composed of the overlap of N submovements:
F tð Þ ¼
XN
i¼1
0 t < T 0i
_x tð Þ T 0i ≤ t ≤T 0i þ D
0 T 0i þ D
8<
:
ð5Þ
Since the robot restrained the movement to the horizon-
tal plane, each movement was implicitly two-dimensional,
so it was defined by four parameters: duration D, starting
time T, and amplitude in x and y direction (Ax and Ay).Submovements were extracted from the measured velocity
profile by using the constrained nonlinear optimization
function (fmincon) in the Optimization toolkit of Matlab
(MathWorks, Natick, MA - USA). For a given number of
submovements, all the parameters were optimized simul-
taneously by minimizing the reconstruction error:
E ¼
X Fx tð Þ−Gx tð Þ½ 2 þ Fy tð Þ−Gy tð Þ 2 þ Fv tð Þ−
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Gx tð Þ2 þ Gy tð Þ2
q 2
2 Gx tð Þ2 þ Gy tð Þ2
 
ð6Þ
where Gx(t) and Gy(t) are the components of the mea-
sured end-effector velocity, Fx(t) and Fy(t) are the recon-
structed x and y components of the velocity, and Fv is
the reconstructed tangential velocity. Referring to the
constraints, submovements were allowed to have a dur-
ation of at least 167 ms, following Rohrer et Hogan [49]; Ax
and Ay, instead, were limited to the size of the workspace,
i.e., between −0.2 m and 0.2 m [50]. The optimization was
run for an increasing number of submovements, until the
error E is lower than a threshold, set to 0.02 [38].
Starting from the obtained submovements, the following
indices were then computed: Number of Submovements
(NS), Duration of Submovements (DS) and Amplitude of
Submovements (AS) [38].
Statistical analysis
All data were tested for normality with the Shapiro-Wilk
test. When the assumption of normality was met, we
assessed the differences between FRDA patients and the
control group by using an independent t-test, with
Welch’s correction when the variances were not equal.
Otherwise, we used a Mann-Withney U test.
Reliability of parameters was analyzed using the Intra-
class Correlation Coefficient (ICC) with an ICC(2,k)
model. Reliability was classified as excellent (ICC ≥ 0.90),
very good (ICC ≥ 0.80), good (ICC ≥ 0.70), moderate
(ICC ≥ 0.6) or poor otherwise.
Finally, within-subject relations between robotic indi-
ces and clinical parameters (disease duration, the smaller
GAA repeat size, the larger GAA repeat size, and the
SARA scale) were tested with a Spearman’s rank order
correlation, with a False Discovery Rate correction for
multiple comparison. The significance level was set at
0.05 for all statistical tests.
Statistical analysis was performed with built-in func-
tions of SPSS 21 (IBM, Armonk, NY - USA).
Results
Robotic indices
Figure 2 show the end-effector trajectories performed
by a representative healthy subject and three patients
with FRDA.
Figure 2 Plot of the path traced by a representative subject from the control group (A), and by three FRDA patients with different SARA scores:
15 (B), 24.5 (C), and 39 (D).
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ces. FRDA patients performed the required task with
higher D values than the control group (FRDA: 2.25 ±
1.04 s; control group: 1.40 ± 0.21 s; U = 247, p < 0.001).
Referring to the velocity profiles, the MV values wereFigure 3 Kinematic indices. Means of the Duration of Movement (left), Me
representing standard error. The symbol * indicates a significant difference be
difference between the two groups (p < 0.001).statistically different between the two groups (FRDA:
0.10 ± 0.02 m/s; control group: 0.12 ± 0.02 m/s; t = 2.644,
p < 0.05); the PV values, instead, were not statistically
meaningful (FRDA: 0.22 ± 0.05 m/s; control group: 0.21 ±
0.03 m/s; t = 1.176, p = 0.249).an Velocity (middle), and Peak Velocity (right), with error bars
tween the two groups (p < 0.05); the symbol *** indicates a significant
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selected indices showed a lower accuracy in the FRDA,
compared with the control group; in fact, LR was higher
in the FRDA patients than in the control group (FRDA:
1.37 ± 0.18; control group: 1.09 ± 0.06; U = 258, p < 0.001);
LD was higher in the FRDA patients than in the con-
trol group (FRDA: 0.72 ± 0.13 cm; control group: 0.50 ±
0.20 cm; U = 213, p < 0.01); and, finally, the AA was
higher in the FRDA patients than in the control
group (FRDA: 9.59 ± 2.20°; control group: 6.85 ± 2.49°;
t = 3.280, p <0.01).
With respect to the movement smoothness (Figure 5),
all the selected indices showed a lower smoothness in
the FRDA, compared with the control group; in fact, NJ
was higher in the FRDA patients than in the control
group (FRDA: 333.24 ± 551.73; control group: 63.73 ±
20.95; U = 256, p < 0.001); SM was lower in the FRDA
patients than in the control group (FRDA: 0.43 ± 0.04;
control group: 0.57 ± 0.06; U = 5, p < 0.001).
The results of the analysis of the submovements
(Figure 6) revealed that movements in FRDA patients
are made of a higher NS value compared to healthy sub-
jects (FRDA: 4.84 ± 2.04; control group: 2.83 ± 0.34; U =
250, p < 0.001); moreover, the mean DS is lower in FRDA
compared with control group (FRDA: 0.60 ± 0.04 s; con-
trol group: 0.67 ± 0.07 s; t = 3.022, p < 0.01). Finally, no
differences were found between the two groups in AS
(FRDA: 0.12 ± 0.03 m/s; control group: 0.14 ± 0.02 m/s;
t = 1.820, p = 0.079).
Test-retest reliability
The ICC values for the selected robotic indices both in
FRDA patients and the control group are reported in
Table 2. With respect to the FRDA group, the ICC
values ranged from 0.686 for the PV (good reliability) to
0.969 for the NS (excellent reliability). With respect to
the healthy subjects, all the selected indices showed aFigure 4 Movement accuracy indices. Means of the Length Ratio (left), Lat
representing standard error. The symbol ** indicates a significant difference
significant difference between the two groups (p < 0.001).very good to excellent reliability: the ICC values ranged
from 0.859 for the LR to 0.992 for the LD.
Correlation analysis
The correlation analysis between robotic indices and
clinical measures is reported in Table 3. The SARA scale
and the upper limb score of the SARA subscale corre-
lated moderately with the D, NJ, and NS. No correlation
was found between the robotic indices and the smaller
GAA repeat size or the larger GAA repeat size. Table 4
shows the correlation analysis for patients older than 10.
From an analysis of this table and a comparative exam
with Table 3, higher values of the Spearman’s correlation
coefficient were found for the D, NJ, and NS indices, if
compared with the ones found for the entire enrolled co-
hort. Moreover, moderate to high values of correlation
were found (see Table 4) between the SARA scale, and the
upper limb score of the SARA scale, with MV, PV, and AS.
Finally, the correlation among the robotic indices for
patients with FRDA is reported in Table 5. High correl-
ation was found between D, MV, PV, LR, NJ, NS and AS.
No correlation or lower correlation was found between
LD, AA, SM, DS and the remaining above-mentioned
indices. DS showed no correlation with all the other
indices. D, MV, NJ, and NS, which show correlation with
the SARA scale, are the indices that showed the highest
correlation between them.
Discussion
In this work, we quantitatively evaluated the upper limb
motor performance in a cohort of individuals affected by
FRDA compared with an age and gender matched control
group of healthy subjects, by using a rehabilitation robotic
device. Specifically, we analyzed the dexterity in perform-
ing a planar point-to-point reaching task, a multijoint
movement that requires the coordination of shoulder and
elbow joint. A similar protocol was efficiently used as aneral Deviation (middle), and Aiming Angle (right), with error bars
between the two groups (p < 0.01); the symbol *** indicates a
Figure 5 Movement smoothness indices. Means of the Normalized Jerk (left) and the Speed Metric (right), with error bars representing standard
error. The symbol *** indicates a significant difference between the two groups (p < 0.001).
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ease, such as stroke, cerebral palsy, or multiple sclerosis
[25,26,29,51]. The test-retest reliability resulted from good
to excellent for most of the chosen indices, ranging from
0.686 to 0.969 for patients with FRDA. These results are
similar to those obtained by Maurel et al. [39], supporting
the introduction of quantitative outcome measures in clin-
ical studies involving patients with FRDA.
The aim of this study was first to verify the sensitivity
of quantitative outcome measures. All the selected
robotic indices, except for two (i.e. the Peak Velocity
and Amplitude of Submovements), were found to be
significantly different between healthy and FRDA pa-
tients, indicating the ability of the selected outcomes to
discriminate between the two groups. In particular, we
also chose redundant indices to better exploit the in-
ternal coherence among indices that are related to
similar feature of the motion. We found that patients
with FRDA showed a significant increase of the Num-
ber of Submovements, and a decrease in their duration
(Duration of Submovements) while the amplitude values
(Amplitude of Submovements) did not show a statisticallyFigure 6 Submovement indices. Means of the Number of Submovements
Submovements (right) with error bars representing standard error. The sym
(p < 0.01); the symbol *** indicates a significant difference between the twsignificant difference. In addition, we found a decrease in
smoothness in patients with FRDA, as highlighted by the
increase in the Normalized Jerk and the decrease in Speed
Metric. Loss of smoothness and increase of submove-
ments in patients with FRDA is probably related both to
the compensative strategy with sudden change of acceler-
ation, and to the decrease of the nervous system control
in correctly planning the movement.
All the selected indices showed a deterioration in
accuracy for patients, compared to healthy subjects.
Actually, trajectories performed by the patients appear
to be more circuitous, as highlighted by both the higher
values of Length Ratio and Lateral Deviation. Moreover,
the increase of the Aiming Angle showed a difficulty in
the planning of the movement, moving the arm toward
the direction of the target. Consequently, the kinematic
indices showed a significant increase in the time
required to reach the target (Duration of Movement),
relative to healthy subjects. These results are in accord-
ance with all the studies that analyzed quantitatively the
movements in patients with FRDA, both in reaching
[3,35,39] and in different tasks [39]. In fact, the slowness(left), Duration of Submovements (middle) and Amplitude of
bol ** indicates a significant difference between the two groups
o groups (p < 0.001).
Table 2 Robotic indices: values of Intraclass Correlation
Coefficient (ICC) for patients with Friedreich’s ataxia and
control group
FRDA Control group
Kinematic indices Duration of Movement 0.918 0.929
Mean Velocity 0.785 0.910
Peak Velocity 0.689 0.895
Accuracy indices Length Ratio 0.802 0.859
Lateral Deviation 0.845 0.992
Aiming Angle 0.818 0.892
Smoothness indices Normalized Jerk 0.879 0.914
Speed Metric 0.686 0.901
Submovement
indices
Number of
Submovements
0.969 0.880
Duration of
Submovements
0.821 0.881
Amplitude of
Submovements
0.831 0.912
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movements, as was also confirmed by other authors
[3,30,32-35].
It is worthy to note that in FRDA the complexity of
the neurological phenotype due to the intricate interplay
between the cerebellar degeneration, the somatosensory
loss and the muscle atrophy does not allow a univocal
interpretation of the results that we obtained. What we
observed, in accordance with the previous study [52]
and in correlation with the status of the disease evalu-
ated by SARA scale, was a progressive deterioration of
the movement. We could speculate that, in accordance
with Corben and colleagues [52], the prolonged move-
ment execution time in FRDA is a likely consequence of
the cerebellar and spinocerebellar dysfunction. In theTable 3 Correlation between robotic indices and clinical para
SARA (total score
Kinematic indices Duration of Movement 0.617*
Mean Velocity −0.542
Peak Velocity −0.480
Accuracy indices Length Ratio 0.355
Lateral 0.134
Aiming Angle 0.029
Smoothness indices Normalized Jerk 0.674*
Speed Metric −0.403
Submovement indices Number of Submovements 0.606*
Duration of Submovements 0.062
Amplitude of Submovements −0.491
Spearman’s rank correlation coefficient are reported. The symbol * indicates a statis
by using a False Discovery Rate procedure).task execution exploited in our research, it is equally
crucial to take into account the role of the visual and
the motor planning impairment, widely already studied
in FRDA [52-56], and not specifically addressed in the
current plan.
The authors [52] suggest that cognitive impairment in
people with FRDA could be related to a disruption of
the cerebro-ponto-cerebello-thalamo-cerebral loops, due
to the cerebellar impairment, reflecting a failure to ac-
cess prefrontal/anterior regions that are necessary for an
effective management of preplanning of movement and
online error correction. fMRI study in healthy young-
adults demonstrates the involvement of the above men-
tioned areas during visual observation of point-to-point
reaching, using InMotion Arm Robotic device, during
both real arm and virtual reaching observation [57].
This also means that healthy young adults, naturally,
associate real and virtual reaching movement, despite
this aspect needs to be deeper addressed in patients
with FRDA.
In our experience, the number and the shape of sub-
movements in reaching tasks in subjects with FRDA
were not yet examined and the only work that analyzed
smoothness in FRDA patients was conducted by Maurel
et al. [39] showing results similar to the ones we de-
scribed. It is worth noting that our set of quantitative in-
dices better provides a measure of smoothness, which
can be useful to quantify the natural progression of the
disease and the eventual benefits of new therapeutic ap-
proaches. Analysis of the results has highlighted that
Duration of Movement, Normalized Jerk and Number of
Submovements were the best discriminative indices, as
they were directly and easily measurable and correlated
with the status of the disease, measured by SARA. Actu-
ally, these measures showed a strong correlation be-
tween them and a moderate correlation with the SARAmeters
) SARA (upper limb) GAA smaller GAA longer Disease duration
0.659* 0.235 −0.361 −0.109
−0.634 −0.417 0.193 0.078
−0.541 −0.200 0.207 0.093
0.363 −0.214 −0.336 −0.208
0.136 0.077 −0.102 −0.399
0.160 0.238 0.224 −0.639
0.739* 0.291 −0.329 −0.118
−0.385 −0.060 0.413 −0.100
0.708* 0.200 −0.266 −0.191
−0.009 0.109 −0.025 −0.051
−0.605 −0.305 0.144 0.062
tical significance, with p < 0.05 (p values are corrected for multiple comparison,
Table 4 Correlation between robotic indices and clinical parameters for patient older than 10 years
SARA (total score) SARA (upper limb) GAA smaller GAA longer Disease duration
Kinematics indices Duration of Movement 0.891** 0.776** 0.117 −0.683 0.106
Mean Velocity −0.818** −0.808** −0.500 0.150 −0.115
Peak Velocity −0.727* −0.690* −0.233 0.117 −0.023
Accuracy indices Length Ratio 0.564 −0.433 −0.433 −0.600 0.065
Lateral Deviation 0.318 0.242 −0.017 −0.517 −0.185
Aiming Angle 0.200 0.205 0.117 −0.217 −0.411
Smoothness indices Normalized Jerk 0.964** 0.904** 0.233 −0.517 0.046
Speed Metric −0.500 0.217 0.217 0.850 −0.259
Submovement indices Number of Submovements 0.927** 0.872** 0.050 −0.567 0.018
Duration of Submovements 0.770 0.014 0.267 0.067 −0.129
Amplitude of Submovements −0.773* −0.772* −0.400 0.117 −0.148
Spearman’s rank correlation coefficient are reported. The symbol * indicates a statistical significance, with p < 0.05; the symbol ** indicates a statistical significance,
with p < 0.01 (p values are corrected for multiple comparison, by using a False Discovery Rate procedure).
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become even stronger if we take into account only the
eleven subjects older than ten years (see Table 4). As has
been reported in the pilot study for age-validation of
SARA [11], functional outcomes appears age-related
under 10 years and are likely to be affected by poor co-
ordination, although not necessarily pathological. In
children, fine motor skills and coordination are related
to the nervous system maturation and particularly to the
cerebellar development that is known to be delayed in
relation to the rest of the brain. Therefore, we argued
that the use of the observed robotic indices in a simple
reaching task for upper limb could be used both in
younger ambulatory patients (older than 10 years) and
in weaker adult patients with limited movements. In par-
ticular our population, although not numerous, was
quite representative of the disease, with a wide range of
locomotor function and disease severity and with typical
onset in the first decade of life. In our opinion it is
worth noting that also for patients with severe impair-
ment, the robotic device is still capable of measuring
movements and providing meaningful data. It is known
that one of the drawbacks of functional scales is the ceil-
ing effect, and also SARA showed a modest ceiling effect
especially for scores greater than 30, namely for most se-
verely affected patients. The analysis of simple indices –
such as Duration of Movement, Normalized Jerk and
Number of Submovements of reaching movement – per-
mits: (i) an objective evaluation of motor performance of
upper limb and (ii) a better exploitation of some features
of ataxic movements that are not fully assessed by the
SARA scale. The previously findings are relevant to ac-
curately and efficiently quantify changes over time also
when the functional scales appear no longer sensitive,
suggesting their use in addition to the traditional evalua-
tions of patients’ dexterity.This work is, to our knowledge, the first study that
quantifies the upper limb motor performance of a sam-
ple of young patients with FRDA by using a robotic de-
vice compared to a clinical functional scale.
However, the small number of our cohort and the lack
of a follow up does not allow us to generalize to a larger
population or to detect the sensitivity to change over
time of these indices. Further analysis is needed to estab-
lish the validity of this robotic tool in a greater cohort of
FRDA patients.
There are other few limitations to the current study
that merit consideration. The first is due to the restric-
tion of the In Motion Arm Robot device that allows the
movement only in the horizontal plane with the involve-
ment of the only proximal limb joints. Distal forearm
and manual dexterity are not involved in the execution
of the task. A further limitation is that, as mentioned be-
fore, in patients with FRDA a lot of complex neuro-
logical components as limb ataxia, sensory loss, difficult
motor planning with slowed information processing,
muscle weakness and not least the visual impairment
could concurrently affect the simple virtual reaching task
selected for this study. Finally, the result of this study
were based on the only dominant limb. In a future longi-
tudinal extension of this work, we will analyze also the
non dominant limb, as suggested by Corben et al. [3].
Furthermore, future study should also address the influ-
ence of specific sensory-motor integration on this task
execution.
Conclusions
Overall, this study shows that the use of robotic indices
may be used as a reliable and sensitive clinical measure-
ment tool for assessing upper limb motor function in
the population with FRDA. Further, the outcome mea-
sures obtained by means of robotic devices can improve
Table 5 Correlation coefficients among the robotic indices for patients with FRDA
Duration of
movement
Mean
velocity
Peak
velocity
Length
ratio
Lateral
deviation
Aiming
angle
Normalized
jerk
Speed
metric
Number of
submovements
Duration of
submovements
Amplitude of
submovements
Duration of movement 1 −0.793** −0.741** 0.771** 0.323 0.200 0.960** −0.604* 0.947** 0.099 −0.758**
Mean velocity −0.793** 1 0.965** −0.327 0.033 0.029 −0.837** 0.182 −0.802** −0.182 0.978**
Peak velocity −0.741** 0.965** 1 −0.297 0.112 0.187 −0.789** 0.108 −0.754** −0.138 0.969**
Length ratio 0.771** −0.327 −0.297 1 0.644* 0.376 0.714* −0.802** 0.754** −0.231 −0.310
Lateral deviation 0.323 0.033 0.112 0.644* 1 0.697* 0.367 −0.618* 0.358 −0.385 0.099
Aiming angle 0.200 0.029 0.187 0.376 0.697* 1 0.226 −0.248 0.270 0.007 0.086
Normalized jerk 0.960** −0.837** −0.789** 0.714* 0.367 0.226 1 −0.547 0.974** −0.059 −0.820**
Speed metric −0.604* 0.182 0.108 −0.802** −0.618* −0.248 −0.547 1 −0.556 0.305 0.125
Number of submovements 0.947** −0.802** −0.754** 0.754** 0.358 0.270 0.974** −0.556 1 −0.077 −0.807**
Duration of submovements 0.099 −0.182 −0.138 −0.231 −0.385 0.007 −0.059 0.305 −0.077 1 −0.103
Amplitude of submovements −0.758** 0.978** 0.969** −0.310 0.099 0.086 −0.820** 0.125 −0.807** −0.103 1
Spearman’s rank correlation coefficient are reported. The symbol * indicates a statistical significance, with p < 0.05; the symbol ** indicates a statistical significance, with p < 0.01 (p values are corrected for multiple
comparison, by using a False Discovery Rate procedure).
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ity, supporting the clinical decision-making, and can ac-
curately and efficiently quantify changes over time in
clinical trials, particularly when functional scales appear
to be no longer sensitive as in the case of patients with
severe functional impairment.
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